OBJECTIVE: Disruption of vitamin D signaling in rodents causes activation of the rennin-angiotensin system (RAS) and development of hypertension. Observational studies in humans found lower circulating 25-hydroxyvitamin D [25(OH)D] is associated with increased RAS activity and blood pressure (BP). We performed the first randomized control trial to investigate the effects of vitamin D supplementation on the RAS in humans. METHODS:Vitamin D deficient, [25(OH)D ≤20 ng/ml), overweight individuals without hypertension were randomized into a double-blind, placebo-controlled trial of 8-weeks treatment with ergocalciferol or placebo. Kidney-specific RAS activity, measured using renal plasma flow response to captopril in high sodium balance, was assessed at baseline and 8 weeks, as was systemic RAS activity and 24-h ambulatory BP. RESULTS: In total, 84 participants completed the study. Mean 25[OH]D levels increased from 14.7 to 30.3 ng/ml in the ergocalciferol group, P value < 0.0001, and from 14.3 to 17.4 ng/ml in the placebo group, P value = 0.3. The renal plasma flow response to captopril was 33.9 ± 56.1 ml/min per 1.73 m at baseline and 35.7 ± 47.7 ml/min per 1.73 m at 8 weeks in the ergocalciferol group (P value = 0.83); and was 37.3 ± 46.9 ml/min per 1.73 m at baseline and 35.9 ± 26.2 ml/min per 1.73 m at 8 weeks in the placebo group (P value = 0.78). Ergocalciferol had no effect on PRA, AngII, or 24-h BP measurements. CONCLUSIONS: This trial found no benefit from correcting vitamin D deficiency on RAS activity or BP after 8 weeks. These findings are not consistent with the hypothesis that vitamin D is a modifiable target for lowering BP in vitamin D deficient individuals.
RCT Entities:
OBJECTIVE: Disruption of vitamin D signaling in rodents causes activation of the rennin-angiotensin system (RAS) and development of hypertension. Observational studies in humans found lower circulating 25-hydroxyvitamin D [25(OH)D] is associated with increased RAS activity and blood pressure (BP). We performed the first randomized control trial to investigate the effects of vitamin D supplementation on the RAS in humans. METHODS:Vitamin D deficient, [25(OH)D ≤20 ng/ml), overweight individuals without hypertension were randomized into a double-blind, placebo-controlled trial of 8-weeks treatment with ergocalciferol or placebo. Kidney-specific RAS activity, measured using renal plasma flow response to captopril in high sodium balance, was assessed at baseline and 8 weeks, as was systemic RAS activity and 24-h ambulatory BP. RESULTS: In total, 84 participants completed the study. Mean 25[OH]D levels increased from 14.7 to 30.3 ng/ml in the ergocalciferol group, P value < 0.0001, and from 14.3 to 17.4 ng/ml in the placebo group, P value = 0.3. The renal plasma flow response to captopril was 33.9 ± 56.1 ml/min per 1.73 m at baseline and 35.7 ± 47.7 ml/min per 1.73 m at 8 weeks in the ergocalciferol group (P value = 0.83); and was 37.3 ± 46.9 ml/min per 1.73 m at baseline and 35.9 ± 26.2 ml/min per 1.73 m at 8 weeks in the placebo group (P value = 0.78). Ergocalciferol had no effect on PRA, AngII, or 24-h BP measurements. CONCLUSIONS: This trial found no benefit from correcting vitamin D deficiency on RAS activity or BP after 8 weeks. These findings are not consistent with the hypothesis that vitamin D is a modifiable target for lowering BP in vitamin D deficient individuals.
Authors: Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams Journal: J Clin Endocrinol Metab Date: 2012-04-26 Impact factor: 5.958
Authors: Rebecca P Gelber; J Michael Gaziano; JoAnn E Manson; Julie E Buring; Howard D Sesso Journal: Am J Hypertens Date: 2007-04 Impact factor: 2.689
Authors: Pankaj Arora; Yanna Song; Jeffery Dusek; Gregory Plotnikoff; Marc S Sabatine; Susan Cheng; Andre Valcour; Heather Swales; Beth Taylor; Erin Carney; Derek Guanaga; Joseph R Young; Courtney Karol; Michael Torre; Atum Azzahir; Semerit M Strachan; Dillon C O'Neill; Myles Wolf; Frank Harrell; Christopher Newton-Cheh; Thomas J Wang Journal: Circulation Date: 2014-10-30 Impact factor: 29.690
Authors: Anand Vaidya; John P Forman; Paul N Hopkins; Ellen W Seely; Jonathan S Williams Journal: J Renin Angiotensin Aldosterone Syst Date: 2011-02-17 Impact factor: 1.636
Authors: Anand Vaidya; Bei Sun; John P Forman; Paul N Hopkins; Nancy J Brown; Nikheel S Kolatkar; Gordon H Williams; Jonathan S Williams Journal: Clin Endocrinol (Oxf) Date: 2011-06 Impact factor: 3.478
Authors: Anne C Looker; Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Mary Frances Picciano; Elizabeth A Yetley Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: A Sadiya; S M Ahmed; M Carlsson; Y Tesfa; M George; S H Ali; H H Siddieg; S Abusnana Journal: Eur J Clin Nutr Date: 2014-11-19 Impact factor: 4.016
Authors: Nehal S Wahba; Salah A Ghareib; Rasha H Abdel-Ghany; Mohamed Abdel-Aal; Amira E Alsemeh Journal: Eur J Nutr Date: 2020-04-22 Impact factor: 5.614
Authors: Rbab Taha; Shahd Abureesh; Shuruq Alghamdi; Rola Y Hassan; Mohamed M Cheikh; Rania A Bagabir; Hani Almoallim; Altaf Abdulkhaliq Journal: Int J Gen Med Date: 2021-07-24
Authors: Keith C Norris; M Edwina Barnett; Yuan-Xiang Meng; David Martins; Susanne B Nicholas; Gary H Gibbons; Jae Eun Lee Journal: Contemp Clin Trials Date: 2018-07-18 Impact factor: 2.261